Physcion increases the sensitivity of hepatocellular carcinoma to sorafenib through miRNA-370/PIM1 axis-regulated glycolysis

BACKGROUND: Resistance to sorafenib has become a challenge in clinical treatment of hepatocellular carcinoma (HCC). Physcion is a common bioactive anthraquinone that has potential as an anticancer agent. AIM: To study the effect of physcion on sensitizing HCC cells to sorafenib. METHODS: Sorafenib-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Xiao-Ping, Jiya, Bu-Ren, Wang, Feng, Lan, Zhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Basic Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473927/
https://www.ncbi.nlm.nih.gov/pubmed/37663938
http://dx.doi.org/10.4251/wjgo.v15.i8.1400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473927/
https://www.ncbi.nlm.nih.gov/pubmed/37663938
http://dx.doi.org/10.4251/wjgo.v15.i8.1400

Ejemplares similares